Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 02, 2025 08:00 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer

Positive feedback reinforces Silexion’s trajectory toward its planned Phase 2/3 trial initiation in Q2 2026 Company plans to complete regulatory submissions to the Israeli Ministry of Health by the...
November 26, 2025 07:30 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference

Grand Cayman, Cayman Islands, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced...
November 25, 2025 09:15 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer

Successful completion of two-species toxicology studies confirms no systemic organ toxicity, advancing the Company towards its planned regulatory submissions to Israel and Germany Company remains on...
November 12, 2025 09:00 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Continued advancement toward Phase 2/3 clinical trial initiation, on track for the first half of 2026 New preclinical data demonstrated SIL204’s exceptional efficacy across multiple human cancer cell...
September 30, 2025 08:40 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer

New data in human cancer cell lines provides confirmation of pan-KRAS mutation inhibition with inhibition of G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D mutations Company Reports first...
September 25, 2025 08:45 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements

GRAND CAYMAN, Cayman Islands, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA...
September 11, 2025 09:17 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Announces Pricing of $6.0 Million Public Offering

Grand Cayman, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion Therapeutics” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi)...
September 11, 2025 07:00 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Reports Positive Preclinical Data Demonstrating SIL204’s Reach and Activity in Major Pancreatic Cancer Metastatic Sites Following Systemic Administration

New Positive Preclinical Data Shows Succesful Drug Distribution to Liver, Peritoneum, and Lung with Measurable Reductions in Tumor Burden at Clinically Relevant Doses Results Provide Further...
September 04, 2025 09:25 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics Announces Selection of Contract Research Organization to Support Upcoming Phase 2/3 Clinical Trials for SIL204

Strategic CRO to Support Path to Phase 2/3 Trials Following Recently Demonstrated Groundbreaking 97% Inhibition Rates for SIL204 Phase 2/3 Clinical Trials Expected to Commence in First Half of 2026...
September 02, 2025 08:45 ET | Source: Silexion Therapeutics Corp

Silexion Therapeutics to Present at the Upcoming 27th Annual H.C. Wainwright Global Investment Conference

Grand Cayman, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi)...